Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting
27.11.2019 14:00:00 EET | Business Wire | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today announced that data from its Kv7 platform will be presented at the American Epilepsy Society’s (AES) 2019 Annual Meeting from December 6-10 in Baltimore.
“We look forward to sharing progress on our lead drug candidate for the treatment of KCNQ2 epileptic encephalopathy as we advance the understanding of ion channel activators and the important role they play in epilepsy and other neurological conditions with high unmet need,” said Michael Bozik, M.D., Chief Executive Officer of Knopp Biosciences.
Ion channels are proteins that regulate the excitability of cells, and drugs that modulate ion channels play an important role in treating a variety of neurological and smooth muscle conditions. Among ion channel targets, potassium channels play a key role in the pathophysiology of epilepsy and other unmet needs in diseases of the nervous system. Knopp is advancing a library of Kv7.2/7.3 channel activators to modulate this key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as other rare epilepsies and neuropathic pain.
Details related to Knopp Biosciences’ AES abstracts and poster presentations can be found in the table below.
Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with AES Annual Meeting news and updates using the hashtag #AES2019.
|
Abstract Title |
Abstract Number / Presentation Details |
|
Discovery and Characterization of KB-3061: A Potent Kv7.2/7.3 Ion Channel Activator for the Treatment of KCNQ2-Neonatal Epileptic Encephalopathy |
Abstract 3.045: Poster Presentation
|
|
KB-3061 is a Potent Activator of Wild Type KCNQ Channels and Restores Current to KCNQ2 Encephalopathy Variants In Vitro
|
Abstract 3.047: Poster Presentation
|
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is in Phase 2 clinical trials for severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, and neuropathic pain. Please visit www.knoppbio.com.
Knopp's Kv7 research is supported under Award Number U44NS093160 and Award Number U44NS115732 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005157/en/
Contact information
Media inquiries:
Kate Coyle
kate.coyle@icrinc.com
203-682-8210
Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vantor, UK Ministry of Defence and Industry Partners Establish Defence Intelligence Innovation Cluster – Project FAIRFAX16.9.2026 11:00:00 EEST | Press release
Vantor, the leader in unified spatial intelligence, announced today it has joined the UK Ministry of Defence and industry partners to launch the UK Defence Intelligence Innovation Cluster, a new collaboration designed to accelerate the development and deployment of next-generation defence and intelligence capabilities and strengthen the UK’s sovereign defence industrial base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916244808/en/ Vantor's Mike Buckley with RAF Wyton officials, council and industry partners at the FAIRFAX Collaboration Hub opening. The cluster is being established through Project FAIRFAX, a joint initiative between the UK Ministry of Defence, Huntingdonshire District Council, Vantor, CGI UK and MAIAR. Together, the founding partners are creating a permanent hub at RAF Wyton where the UK government, industry and academia can work together on operational challenges, evaluate emerging technologies and a
More than Half of Consumers are Comfortable with AI Agents Applying for Credit, Experian Research Finds16.9.2026 11:00:00 EEST | Press release
Consumers are ready to take the next step in their relationship with artificial intelligence (AI), according to AI in Risk: The Rise of Agentic Commerce, new research from data and technology company, Experian, conducted by Forrester Consulting. The study of 6,247 credit-active consumers across 13 EMEA and Asia Pacific markets, found that more than half (54%) of respondents are comfortable with AI agents applying for credit on their behalf. The findings point to the next stage in the evolution of financial services, where consumers are becoming comfortable allowing AI to move beyond providing information to supporting parts of the lending journey, including comparing lenders, checking eligibility, completing applications and securely submitting authorised documents. "Consumers are already changing the way they engage with financial services," said Mariana Pinheiro, Chief Executive Officer, Experian EMEA & Asia Pacific. "They are not just experimenting with AI anymore; they are beginnin
Aqara Announces the Availability of The Spatial Multi-Sensor FP400, Offering Advanced Spatial Intelligence for Smart Homes16.9.2026 10:00:00 EEST | Press release
Aqara, a global leader and pioneer in IoT, today announced the release of the Spatial Multi-Sensor FP400. The FP400 is designed to bring precise, spatial intelligence to homes without sacrificing the privacy typically compromised by smart cameras. Rather than simply detecting motion or presence, the FP400 enables homes to better understand occupancy, movement, and context for more granular and personalized automations and insight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916958372/en/ Aqara Announces the Availability of The Spatial Multi-Sensor FP400, Offering Advanced Spatial Intelligence for Smart Homes The Spatial Multi-Sensor FP400 redefines how smart homes perceive and interact with living spaces by combining high-precision spatial sensing with AI-powered environmental understanding. Powered by a next-generation high-precision 60GHz mmWave radar, the FP400 delivers industry-leading multi-person sensing, precise
Cambridge Associates Opens Italian Office and Expands European Leadership16.9.2026 10:00:00 EEST | Press release
Global investment firm Cambridge Associates (CA) today announced the opening of a new office in Milan and the appointment of two senior hires in Europe. The move reflects the firm’s ongoing commitment to providing bespoke services to current and future institutional and family office investors across the region. Raphael Heynold has joined the Client Solutions team as Head of EMEA and APAC and will serve on the firm’s EMEA Operating Committee. Based in London, Raphael is a key member of the Global Client Solutions Leadership team, responsible for driving growth and market expansion and overseeing client engagement efforts across Europe, the Middle East, and Asia Pacific regions. Heynold brings more than 30 years of experience across client strategy, investment banking and investment management, and has worked with many sophisticated families and institutions around the world. Riccardo Pianeti has joined Cambridge Associates to lead the Italian office. He will serve as Head of the Milan
International Expansion Far Outweighs M&A as a Legal and Compliance Execution Burden, CSC Research Finds16.9.2026 09:49:00 EEST | Press release
International expansion is creating a far heavier legal and compliance execution burden than M&A itself, with nearly three quarters (74%) of senior cross-border professionals citing market entry or international expansion as a leading burden, compared with just 28% for M&A transactions, according to new research from CSC, the leading provider of global business administration and compliance solutions. The challenge extends well beyond deal execution. Ongoing entity governance and compliance is cited by 71% of respondents, highlighting the operational burden of establishing and maintaining a presence across multiple jurisdictions. CSC’s new report, The Cross-Border Readiness Gap: Navigating the Legal and Compliance Burden of International Expansion, draws on the views of 200 senior professionals globally with direct experience of cross-border transactions, expansion, restructuring, and entity or compliance work. Fragmented entity and ownership information is a major source of that compl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom